Skip to main content
Clinical Trials/IRCT2014050511375N3
IRCT2014050511375N3
Completed
Phase 3

The Effect of Angiotensin Converting Enzyme Inhibitor on the Quality of Life of Non Hospitalized Patients With Cancer Cachexia

Shiraz University of Midical Sciences0 sites40 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Gastric cancer.
Sponsor
Shiraz University of Midical Sciences
Enrollment
40
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Shiraz University of Midical Sciences

Eligibility Criteria

Inclusion Criteria

  • Inclusion Criteria: Patients with aged 40\-80 years old; Patients with BMI less 18 and those with muscle wasting or only temporal wasting.

Exclusion Criteria

  • Patients unable to continue the treatment; Patients with BMI more 18 without temporal or muscle wasting; Those with GFR less 50 ml/min; Positive history of other co\-morbidity diseases; Patients with Hb less 9; Patients unavailable for or incapable of filling out questionnaires at different intervals.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Effect of Angiotensin Converting Enzyme Inhibition (ACEI) on C-Reactive Protein (CRP) Levels: The Ramipril CRP Randomized Evaluation (4R Trial)Healthy volunteers with elevated levels of C-Reactive proteinCirculatory System
ISRCTN31129526Sanofi-Aventis (Canada)400
Recruiting
Not Applicable
Benefit and Harm of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in COVID-19 Patients: A Review Protocol of Systematic Review and Meta-AnalysisThere is a controversial debate regarding how to treat cardiovascular disease in COVID-19 confirmed patients. Ones documented that ACE inhibitor may increase risk of fatal COVID-19 by serving entry site for this virus, on contrary ones documented that ACEi and/or ARB may be beneficial for Acute Lung Injury and cardiovascular protection.
JPRN-UMIN000041430Faculty of Medicine, Universitas Airlangga
Terminated
Not Applicable
ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty PatientsAdverse Effects of Angiotensin-converting-enzyme InhibitorsHypotension
NCT01867047Duke University59
Completed
Phase 3
Effect of Angiotensin-converting enzyme and ß-blockers on the prognosis of severe isolated brain traumaS06.2XDiffuse traumatic brain injurySevere isolated brain trauma.
IRCT20210514051289N1Esfahan University of Medical Sciences96
Active, not recruiting
Phase 1
Angiotensin Converting Enzyme Inhibitor (ACE) Induced AngioedemaBERINERTRandomized, double-blind, two arms, multicenter, Phase III study of Berinert for treatment of ACE induced AngioedemaAngiotensin – Converting – Enzyme – Inhibitors (ACEi) are used in the treatment of several types of cardiovascular and renal diseases. A known side effect of ACEi are angioedema of the head and neck region. These can lead to severe dyspnoea and the need for intubation and are thought to be bradykinin mediated. Up until now there is no study-evaluated conservative therapeutic concept for the treatment of these patients.MedDRA version: 18.1Level: HLTClassification code 10002425Term: AngioedemasSystem Organ Class: 100000004870Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2012-001670-28-DEMedizinische Fakultät der Technischen Universität München52